MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/bjc.2017.290

Медицинская библиотека · British journal of cancer · 2017

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.

Joensuu Heikki, Blay Jean-Yves, Comandone Alessandro, Martin-Broto Javier, Fumagalli Elena, Grignani Giovanni, Del Muro Xavier Garcia, Adenis Antoine, Valverde Claudia, Pousa Antonio Lopez, Bouché Olivier, Italiano Antoine, Bauer Sebastian, Barone Carlo, Weiss Claudia, Crippa Stefania, Camozzi Maura, Castellana Ramon, Le Cesne Axel

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

This multicentre phase II trial (DOVIGIST) evaluated the antitumour activity of dovitinib as second-line treatment of patients with gastrointestinal stromal tumour (GIST) refractory to imatinib or who do not tolerate imatinib.

METHODS

Patients received oral dovitinib 500 mg day-1, 5 days on/2 days off, until GIST progression or unacceptable toxicity, with an objective to evaluate efficacy, assessed as the disease control rate (DCR) at 12 weeks. Tumour assessment and response to dovitinib therapy were evaluated by Response Evaluation Criteria In Solid Tumours (RECIST v1.1) and the Choi criteria. Secondary objectives included assessment of progression-free survival (PFS), safety and tolerability, and DCR at the end of treatment.

RESULTS

Thirty-eight of the 39 patients enrolled had histologically confirmed GIST. The DCR at 12 weeks was 52.6% (90% confidence interval (CI), 38.2-66.7%) meeting the preset efficacy criterion for the primary end point. The objective response rate (complete response+partial response) was 2.6% (1 of 38; 90% CI, 0.1-11.9%), and 5.3% (n=2; 90% CI, 0.9-15.7%) at the end of the study. The median PFS was 4.6 months (90% CI, 2.8-7.4 months). Dose interruption was required in 26 patients (66.7%), of which 18 (69.2%) were due to adverse events. The most frequently observed grade 3 adverse events included hypertension (n=7), fatigue (n=5), vomiting (n=4), hypertriglyceridaemia (n=4), and γ-glutamyltransferase increase (n=4).

CONCLUSIONS

Dovitinib is an active treatment for patients with GIST who are intolerant to imatinib or whose GIST progresses on imatinib.

Для цитирования: Joensuu Heikki, Blay Jean-Yves, Comandone Alessandro, Martin-Broto Javier, Fumagalli Elena, Grignani Giovanni, Del Muro Xavier Garcia, Adenis Antoine, Valverde Claudia, Pousa Antonio Lopez, Bouché Olivier, Italiano Antoine, Bauer Sebastian, Barone Carlo, Weiss Claudia, Crippa Stefania, Camozzi Maura, Castellana Ramon, Le Cesne Axel. Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.. British journal of cancer. 2017. DOI: 10.1038/bjc.2017.290.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.